>>>> News Agenda Subscribe to news Get to know AsiDNA View corporate presentation BECOME A PARTNER BECOME A SHAREHOLDER NEWS > Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag® AGENDA > French Society of Financial Analysts meeting: Strategic Portfolio & Newsflow Update October 2nd, 2017 back up ↑ Terms of use Contact © Copyright 2017 onxeo | The sections “The group”, “Our products”, “Partnerships”, “Investors”, “Media” are dedicated to investors. | Webdesign : Limbus Studio